NALIRIFOX
NALIRIFOX is a pharmaceutical drug with 9 clinical trials. Currently 9 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
4
Early Stage
4
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
9
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial
Clinical Trials (9)
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial
Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9